Say goodbye to night time devices – Say hello to daytime therapy.
eXciteOSA® for mild sleep apnoea delivers NMES therapy and has been clinically proven to reduce sleep apnoea. Use for just 20 minutes a day, every day for six weeks, to improve the quality of your sleep.1-2
Clinically proven daytime therapy. Nothing to wear at night.1-2
There are several options for treating mild obstructive sleep apnoea
Many OSA therapies focus on creating space in the airway. NMES does something unique.
1. Nighttime treatments
Uncomfortable. Difficult to tolerate
Mandibular (jaw) Advancement Device works by temporarily moving the jaw forward. CPAP machine pumps air at pressure into your upper airway.
2. Surgical treatments
Surgery is usually an option after other treatments have failed. Examples include tissue or tonsil removal.
3. Daytime NMES therapy
Simple, effective & painless
NMES physiologically retrains the upper airway and tongue, to stay in its natural position while you sleep.
eXciteOSA For Sleep Apnoea – A Daytime Therapy
Neuromuscular electrical stimulation (NMES) with eXciteOSA®
NMES safely activates nerves and trains muscles. NMES is a familiar and well-established technique in medicine and athletics.
Sleep apnoea has multiple causes, including reduced responsiveness of the tongue and upper airway muscles3.
NMES is different
Convenient daytime therapy
Comfortable and painless leaving you with nothing to wear at night.
A recent study found a 52% reduction in the AHI and a 50% reduction in the ODI amongst responders – all without a CPAP or MAD4.
Retrains the upper airway
Physiologically retrains the upper airway. No other device currently on the market does that.
You are in control
Use the app to control the intensity of the stimulation and get guidance, reminders and notifications about your therapy.
Pay later with Klarna & Paypal Paylater
Spread payments over 6, 12, 24 or 36 months with (Klarna) or split by 3 months (Paypal Paylater)
The Klarna and Paypal Paylater options will appear after entering your details via checkout.
Hear how eXciteOSA® has transformed peoples sleep
“I have this simple device… [that] I use during the day [so] that I can sleep quite happily without thinking about having to wear a mask at night.”
Find a Therapy That Works for You
OSA is a progressive disease that should be treated5-8
With new alternatives available, like daytime therapy, there is now no excuse. Consult your physician as, if left untreated, OSA places extra strain on your health.
Trusted by Experts
Backed by leading sleep specialists
“We believe that eXciteOSA® therapy will be able to help many patients in the near future.”
- Specialist in ORL at Dr. Peset University Hospital, Valencia, Spain
- Expert in Sleep Medicine
- President of the Commission on Roncopathy and Sleep Apnoea of the Spanish Society of Otolaryngology and Head and Neck Surgery
“I am optimistic that this treatment will be an important treatment approach for patients with with mild sleep apnea and snoring.”
- M.D. Research Chief, Pulmonary, Critical Care and Sleep Medicine
- Peter C. Farrell Presidential Chair and Professor in Respiratory Medicine
- Former President, American Thoracic Society 2015- 2016
Frequently asked questions
Transcutaneous electrical nerve stimulation (TENS) machines stimulates the sensory nerves (the nerves that send signals from the body to the brain) with the purpose of disrupting the pain signal.
Neuromuscular electrical stimulation (NMES) also uses electrical stimulation, but targets the motor nerves (the nerves that send signals from the brain to the body) in order to stimulate the muscles directly.
Sensory and motor nerves fire at different frequencies, which is how TENS and NMES devices are able to impact them differently.
eXciteOSA® is a user-controllable neuromuscular electrical stimulator (NMES) that delivers a mild electrical current with defined frequencies to stimulate and improve muscle function in the mouth and tongue.
Unlike traditional sleep apnoea treatments, eXciteOSA® targets the tongue to promote endurance of the muscle, thereby reducing airway collapse and snoring during sleep.
A daytime therapy with no night-time wearable necessary for a better night’s sleep.
There are several options for treating sleep apnea.
Manudibular advancement devices (MADs) work by temporarily moving the jaw forward, in order to create more space in the airway.
CPAP delivers air pressure through a mask to open up the airway.
Surgery is usually an option to consider after other treatments have failed. Examples include removal of soft tissues from the airway, or procedures designed to stiffen the airway.
NMES physiologically retrains the upper airway and tongue to maintain the tongue’s natural position while you sleep, effectively helping your body help itself. eXciteOSA For Sleep Apnoea is the only device that delivers NMES. You can also refer to the chart above to better illustrate the main difference.
Speak to an expert
Speak to one of our patient advocates for a no-obligation discussion around your needs for a better night’s sleep.
* Terms and Conditions of the Sleep Guarantee: You must start using the exciteOSA For Sleep Apnoea within 1 x calendar week of receiving your eXciteOSA. For optimal results, you should use it every day for 6 weeks. However, we know that we are all only human and people forget things – so we ask that you use it for a total of 6 weeks (a total of 42 days) within an 8 week period (56 days). A session is equivalent to 20 minutes. In addition, it is recommended that you increase the therapy intensity gradually over the treatment period to ensure that you give the treatment every chance of being effective. Please note that once the initial therapy is finished and to maintain the treatment you need to use the device at least twice a week forever.
The mouthpiece is a precision piece of engineering responsible for delivering neuromuscular electrical stimulation targeted primarily at the tongue. It needs to be replaced every 3 months and therefore will not be refunded as part of the ‘try before you buy offer’. We will deduct £54 + VAT from the final refund amount. Signifier will send you a return label for the device to be returned. Please contact Signifier Medical to arrange this.
- Kotecha, B., Wong, P.Y., Zhang, H. et al. A novel intraoral neuromuscular stimulation device for treating sleep-disordered breathing. Sleep and Breathing (2021). https://doi.org/10.1007/s11325-021-02355-7
- Baptista et al. Daytime Neuromuscular Electrical Therapy of Tongue Muscles in Improving Snoring. Journal of Clinical Medicine (2021)
- Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med 2013;188(8):996-1004
- Based on analysis of n=65 participants with mild OSA recruited from multiple UK and European sites, who underwent a single-arm trial of eXciteOSA for a duration of six weeks between February 2019 and April 2020. Data on file.
- Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015-3021
- Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-1239
- Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005;165:2408-2413
- Redline S, Schluchter MD, Larkin EK, Tishler PV. Predictors of longitudinal change in sleep-disordered breathing in a nonclinic population. Sleep 2003;26:703-709
- Vgontzas AN, Li Y, He F, Fernandez-Mendoza J, Gaines J, Liao D, Basta M, Bixler EO. Mild-to-moderate sleep apnea is associated with incident hypertension: age effect. Sleep 2019;42
- Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type 2 diabetes: A population-based study. Am J Respir Crit Care Med 172(12):1590-1595 (2005)
- Bubu OM, Brannick M, Mortimer J, et al. Sleep, Cognitive impairment, and Alzheimer’s disease: A Systematic Review and Meta-Analysis. Sleep 2017;40(1):